BPMC: Blueprint Medicines Corp.
About
Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.
Current Value
$94.161 Year Return
Current Value
$94.161 Year Return
Key Details
Market Cap
$6.01B
P/E Ratio
-44.88
1Y Stock Return
42.68%
1Y Revenue Growth
100.93%
Dividend Yield
0.00%
Price to Book
19.2
Strategies that include BPMC
Stock's related to BPMC
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BELFB | 48.59% | $903.17M | +35.81% | 0.38% |
| BHE | 47.58% | $1.70B | +86.81% | 1.41% |
| SW | 47.38% | $13.78B | +15.02% | 1.14% |
| AIN | 47.32% | $2.61B | -0.13% | 1.26% |
| DLX | 47.23% | $1.01B | +24.44% | 5.30% |
| BBIO | 46.45% | $4.26B | -20.38% | 0.00% |
| STC | 46.40% | $2.02B | +61.68% | 2.65% |
| ZD | 46.02% | $2.37B | -14.73% | 0.00% |
| ADEA | 45.48% | $1.20B | +17.45% | 1.74% |
| ASB | 45.28% | $3.95B | +48.10% | 3.36% |
| IAC | 45.20% | $4.11B | -0.75% | 0.00% |
| KN | 44.62% | $1.60B | +12.19% | 0.00% |
| VSH | 44.18% | $2.07B | -31.61% | 2.64% |
| CTS | 44.14% | $1.58B | +33.53% | 0.30% |
| HOMB | 44.13% | $6.11B | +41.20% | 2.45% |
| CFFN | 44.10% | $893.32M | +29.42% | 5.07% |
| TCBK | 44.08% | $1.55B | +31.56% | 2.74% |
| PJT | 44.03% | $3.69B | +85.94% | 0.65% |
| COHU | 44.02% | $1.18B | -22.38% | 0.00% |
| ALRM | 44.01% | $2.95B | +3.34% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AQB | -0.02% | $3.78M | -37.77% | 0.00% |
| LUMO | -0.04% | $37.45M | +41.97% | 0.00% |
| XPEL | 0.06% | $1.18B | -7.73% | 0.00% |
| SCKT | -0.10% | $10.88M | +15.32% | 0.00% |
| SOLV | -0.13% | $11.58B | -16.19% | 0.00% |
| HRL | 0.15% | $16.30B | -8.38% | 3.81% |
| KRRO | -0.18% | $436.84M | +20.68% | 0.00% |
| NERV | 0.19% | $14.69M | -58.00% | 0.00% |
| TPST | -0.23% | $37.75M | -77.59% | 0.00% |
| IMNN | -0.27% | $10.02M | -22.89% | 0.00% |
| VHC | -0.28% | $19.06M | -38.36% | 0.00% |
| NTZ | 0.36% | $47.64M | -30.94% | 0.00% |
| ASPS | 0.36% | $22.36M | -80.26% | 0.00% |
| OCX | 0.41% | $42.93M | -36.09% | 0.00% |
| BNED | 0.41% | $277.22M | -91.94% | 0.00% |
| NVO | -0.50% | $342.62B | -0.15% | 1.40% |
| SITC | 0.52% | $847.27M | +59.73% | 2.42% |
| UAN | 0.57% | $753.51M | -1.90% | 9.38% |
| CANG | 0.58% | $253.50M | +212.50% | 0.00% |
| WM | -0.60% | $87.92B | +27.58% | 1.34% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MO | -19.53% | $94.67B | +37.05% | 7.07% |
| CBOE | -13.06% | $21.46B | +15.84% | 1.11% |
| CYCN | -12.74% | $4.77M | -16.19% | 0.00% |
| COR | -11.77% | $47.48B | +21.20% | 0.86% |
| STG | -11.14% | $35.67M | +7.92% | 0.00% |
| HUSA | -10.44% | $16.69M | -11.56% | 0.00% |
| WST | -9.41% | $22.02B | -13.73% | 0.27% |
| TAK | -9.29% | $43.18B | -2.85% | 2.17% |
| PRPO | -9.23% | $9.10M | -13.65% | 0.00% |
| MA | -8.45% | $476.78B | +27.02% | 0.51% |
| VSTS | -7.39% | $1.76B | -18.18% | 1.04% |
| FSLY | -7.05% | $941.41M | -61.50% | 0.00% |
| ALGN | -6.87% | $16.62B | +3.38% | 0.00% |
| MNR | -6.86% | $1.66B | -10.71% | 15.90% |
| UUU | -6.52% | $4.97M | -41.89% | 0.00% |
| BMY | -6.45% | $118.10B | +20.11% | 4.09% |
| MNOV | -6.40% | $93.19M | +2.15% | 0.00% |
| WU | -6.29% | $3.63B | -9.74% | 8.78% |
| PEP | -5.66% | $215.02B | -6.60% | 3.35% |
| PG | -5.57% | $402.15B | +14.14% | 2.33% |
ETF's related to BPMC
News
SeekingAlpha
Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a strong buy amid high cash burn.
Yahoo
JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune mast cells. In 2023, the FDA approved Blueprint Medicines’ Ayvakit (avapritinib) as the first, only treatment for indolent systemic mastocytosis (ISM). In the third quarter of 2024, Ayvakit reported net product revenues of $128.2 million, including $113.1 million in the U.S. and $15.1 million ex-U.S., representing 136% growth year over year. Blueprint Medicines anticipate
SeekingAlpha
Healthcare stocks performed well during Trump's first term, despite increased uninsured rates and reduced regulation. Click here for a detailed analysis.
Yahoo
It's been a good week for Blueprint Medicines Corporation ( NASDAQ:BPMC ) shareholders, because the company has just...
Yahoo
Over the last 7 days, the United States market has dropped 1.6%, but over the longer term, it has risen by 30% in the past year with earnings forecast to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and potential for sustained revenue expansion in alignment with these market trends.
Yahoo
Blueprint Medicines ( NASDAQ:BPMC ) Third Quarter 2024 Results Key Financial Results Revenue: US$128.2m (up 127% from...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.